Breaking News Instant updates and real-time market news.

ACB

Aurora Cannabis

$2.06

0.27 (15.08%)

, XLY

Consumer Discretionary Sector SPDR

$126.42

-0.29 (-0.23%)

04:55
01/16/20
01/16
04:55
01/16/20
04:55

AltaCorp/ATB to hold a conference

AltaCorp/ATB 2020 Outlook Conference will be held in Toronto on January 14-16.

ACB

Aurora Cannabis

$2.06

0.27 (15.08%)

XLY

Consumer Discretionary Sector SPDR

$126.42

-0.29 (-0.23%)

LABS

LabOne Inc

$0.00

(0.00%)

IAN

Inter-Atlantic Financial

$0.00

(0.00%)

CGC

Canopy Growth

$24.88

1.03 (4.32%)

WL

Wilmington Trust

$0.00

(0.00%)

FIRE

SourceFire

$0.00

(0.00%)

SNDL

Sundial Growers

$3.37

0.505 (17.63%)

VIVO

Meridian Bioscience

$9.91

0.04 (0.41%)

TER

Teradyne

$69.11

-1.13 (-1.61%)

FAF

First American

$59.10

0.45 (0.77%)

META

Metatec

$0.00

(0.00%)

KHRNF

Khiron Life Sciences

$0.00

(0.00%)

  • 23

    Jan

  • 29

    Jan

  • 07

    Feb

  • 13

    Feb

  • 21

    Feb

ACB Aurora Cannabis
$2.06

0.27 (15.08%)

01/09/20
PIPR
01/09/20
DOWNGRADE
Target $1
PIPR
Underweight
Aurora Cannabis downgraded to Underweight from Neutral at Piper Sandler
Piper Sandler analyst Michael Lavery downgraded Aurora Cannabis to Underweight from Neutral with a price target of $1, down from $3. The shares closed Thursday up 12c to $1.86. The company's cash flow and balance sheet outlooks pose risks, Lavery tells investors in a research note. Aurora's balance sheet is a risk as its cash from operations is unlikely to turn positive until fiscal Q3 of 2021, Lavery tells investors in a research note. The analyst expects the company will have to refinance $360M of debt due in August 2021, which he feels could be challenging in this environment.
01/10/20
BOFA
01/10/20
DOWNGRADE
Target $1
BOFA
Underperform
Aurora Cannabis downgraded to Underperform from Neutral at BofA
BofA analyst Christopher Carey downgraded Aurora Cannabis to Underperform from Neutral with a $1.00 price target. While shares have underperformed since his last downgrade, with balance sheet risks to remain a core investment thesis in 2020 and lingering uncertainty especially on financial covenants, Carey says he struggles to envision a scenario where shares have sustainable support.
01/13/20
CANT
01/13/20
NO CHANGE
Target $5
CANT
Overweight
Aurora Cannabis selloff a buying opportunity, says Cantor Fitzgerald
Cantor Fitzgerald analyst Pablo Zuanic would use the recent weakness in shares as a buying opportunity. Poor liquidity makes the stock sensitive to downgrades and "misplaced market chatter," Zuanic tells investors in a research note. The departure of Cam Battley was good news, a planned asset sale is being done pretty much at book value, and debt covenants imply positive EBITDA by mid-year, contends the analyst, who has "increased conviction" on the shares after speaking to management. Battley was let go, he did not resign as the market seems to have speculated, says Zuanic. The analyst senses a greater focus and a greater urgency regarding costs and cash flow at Aurora Cannabis and keeps an Overweight rating on the shares with a C$5 price target.
01/02/20
CANT
01/02/20
NO CHANGE
Target $5
CANT
Overweight
Cantor says time for Peltz to call on Aurora to show financial discipline
Cantor Fitzgerald analyst Pablo Zuanic said he thinks it is time for Nelson Peltz, who is being paid as a consultant at Aurora Cannabis (ACB), to call for the same type of greater financial discipline at the company that the shareholder activist previously advocated for at companies like Heinz (KHC), PepsiCo (PEP) and Mondelez (MDLZ). Zuanic, who thinks Aurora's below-peer valuation reflects no optionality from the entry of a consumer packaged goods investor or from the increased financial discipline a new CEO could bring, keeps an Overweight rating on the shares, though he lowered his price target to C$5.00 from C$5.85.
XLY Consumer Discretionary Sector SPDR
$126.42

-0.29 (-0.23%)

LABS LabOne Inc
$0.00

(0.00%)

IAN Inter-Atlantic Financial
$0.00

(0.00%)

CGC Canopy Growth
$24.88

1.03 (4.32%)

01/10/20
ARGS
01/10/20
DOWNGRADE
ARGS
Hold
Constellation Brands downgraded to Hold from Buy at Argus
Argus analyst John Staszak downgraded Constellation Brands (STZ) to Hold from Buy following the company's quarterly results. In a research note to investors, Staszak says that despite a strong Q3, he thinks further upward revisions to guidance are "unlikely" in fiscal 2021 and he worries that beer sales could decelerate and divestitures in the wine and spirits division could continue to be a headwind. Additionally, he says the company's investment in Canopy Growth (CGC) reduced earnings in Q3 by 25c and should continue to pressure earnings amid a large number of competitors.
12/12/19
CANT
12/12/19
NO CHANGE
Target $27
CANT
Neutral
Canopy Growth price target raised to C$27 from C$18.90 at Cantor Fitzgerald
Cantor Fitzgerald analyst Pablo Zuanic raised his price target for Canopy Growth (CGC) to C$27 from C$18.90 and keeps a Neutral rating on the shares after meeting with management. The analyst assumes a C$31 potential takeover price and assigns a 65% probability to a deal happening. Constellation Brands (STZ) has confirmed it will contribute further cash to Canopy at some point via the outstanding warrants. However, it could take control of the company with less cash disbursement given the strike prices are up to three times above current levels, Zuanic tells investors in a research note.
12/09/19
CANT
12/09/19
NO CHANGE
Target $18.9
CANT
Neutral
Cantor sees over 66% chance of Constellation bidding for Canopy Growth
Cantor Fitzgerald analyst Pablo Zuanic is surprised it has taken this long for Constellation Brands (STZ) to appoint a new CEO at Canopy Growth (CGC) following the exit of Bruce Linton. Pundits trying to read the tea leaves could make arguments both pro and con regarding whether the probability of a bid for the entire company by Constellation has increased or not, Zuanic tells investors in a research note. For his part, the analyst thinks the probability of Constellation trying to acquire Canopy has increased. However, he admits it is not an easy strategic decision for Constellation given its balance sheet, likely mid- to high-teens earnings dilution from a deal for the 65% of Canopy it does not own, and likely near-term hit to its own share price. Nonetheless, Zuanic assigns a more than two-thirds probability to Constellation putting in a bid for all of the Canopy Growth equity in the near term. On the argument of an improving outlook for the cannabis industry, Constellation could justify a deal, contends the analyst, who has a Neutral rating on Canopy Growth with a C$18.90 price target.
11/22/19
MKMP
11/22/19
NO CHANGE
MKMP
Canopy Growth, Aurora Cannabis profitability hard to achieve, MKM Partners says
MKM Partners analyst Bill Kirk remains cautious on Canadian Cannabis producers, saying that consensus expectations are still "high as a kite". The analyst notes that the sector has recently rebounded to "prior earnings level share prices", but believes that the assumption of "massive revenue growth with hardly any absolute cost growth" embedded in consensus is "very unlikely". Kirk cites fresh signs of cracks in the Canada market - namely that pricing is down, gaps to illicit aren't closing, and consumption per federal license is contracting - which suggests that the near-term path to profitability looks challenged. Kirk keeps his Neutral rating and CAD23 price target on Canopy Growth (CGC) and Sells rating with CAD3 price target on Aurora (ACB).
WL Wilmington Trust
$0.00

(0.00%)

FIRE SourceFire
$0.00

(0.00%)

SNDL Sundial Growers
$3.37

0.505 (17.63%)

09/27/19
LEHM
09/27/19
INITIATION
Target $7
LEHM
Overweight
Sundial Growers initiated with an Overweight at Barclays
Barclays analyst Lauren Lieberman initiated Sundial Growers with an Overweight rating and $7 price target, citing her view that the company can set itself apart from peers given a focus on profitable growth. Sundial is already nearly profitable in its Canadian home market, noted Lieberman, who thinks its acquisition of Bridge Farm should enable the company to ultimately become a low-cost mass-scale producer of CBD products.
10/31/19
BMOC
10/31/19
DOWNGRADE
Target $4
BMOC
Market Perform
BMO downgrades Sundial Growers to Market Perform on lower cannabis demand
BMO Capital analyst Tamy Chen downgraded Sundial Growers to Market Perform from Outperform with a price target of $4, down from $8. Recent developments suggest there is now less demand and lower pricing in the licensed cannabis producer to licensed cannabis producer market as more producers have ramped production, Chen tells investors in a research note. The analyst points out that the producer-to-producer channel represents the majority of Sundial's current revenues. As a result, Chen believes Sundial will continue to be attributed a lower relative multiple until the company can demonstrate a "clearer pathway towards a meaningful presence" in the recreational cannabis market.
10/30/19
BMOC
10/30/19
DOWNGRADE
BMOC
Market Perform
Sundial Growers downgraded to Market Perform from Outperform at BMO Capital
09/10/19
BMOC
09/10/19
UPGRADE
BMOC
Outperform
BMO upgrades Sundial Growers to Outperform after share decline
BMO Capital analyst Tamy Chen last night upgraded Sundial Growers to Outperform from Market Perform with an unchanged price target of $12. The current valuation implies 2020 revenues of C$220M, says the analyst, which is well below her forecast of C$490M. While there remains execution uncertainty in the industry, Sundial shares are now reflecting an overly cautious revenue outlook in the context of the company's results to date, Chen tells investors in a research note. As a result, the analyst believes the current stock price "could offer a stronger return relative to some of its peers."
VIVO Meridian Bioscience
$9.91

0.04 (0.41%)

04/03/19
ADAM
04/03/19
DOWNGRADE
ADAM
Sell
Meridian Bioscience downgraded to Sell from Hold at Canaccord
04/03/19
ADAM
04/03/19
DOWNGRADE
Target $11
ADAM
Sell
Meridian Bioscience downgraded to Sell from Hold at Canaccord
Canaccord analyst Mark Massaro downgraded Meridian Bioscience to Sell from Hold and lowered his price target to $11 from $17, saying he believes a turnaround is not going to occur in the near-term and, if it is possible, it is likely one to two years away. Massaro tells investors that his concerns are "heightened" after Meridian delivered its second quarterly preannounced to-line miss and fiscal year guide down, and disclosed additional challenges, including rising competition in its life sciences segment from China, and the additional information hold by the FDA on its 510(k) applications to reinstate its venous blood sample-type. Additionally, the analyst says he is concerned about forward year operating margins and earnings.
04/03/19
BARD
04/03/19
NO CHANGE
Target $14
BARD
Neutral
Meridian Bioscience price target cut to $14 from $17 at Baird
Baird analyst Catherine Ramsey Schulte lowered her price target on Meridian Bioscience to $14 from $17 and maintained a Neutral rating after the company reported preliminary Q2 revenue well below the Street, with the miss mostly driven by Diagnostics, with particular weakness in molecular and respiratory issues. The analyst says she remains on the sidelines, as she believes ongoing headwinds are likely to persist near-term and management's new strategy will likely take time to drive better results.
05/01/19
PIPR
05/01/19
UPGRADE
Target $11
PIPR
Neutral
Meridian Bioscience upgraded to Neutral from Underweight at Piper Jaffray
Piper Jaffray analyst William Quirk upgraded Meridian Bioscience to Neutral from Underweight while lowering his price target for the shares to $11 from $15. The analyst applauds management's decision to suspend the dividend. The previous capital allocation model was not working and was "suffocating the business," Quirk tells investors in a research note. He's encouraged management is "rebuilding the growth story."
TER Teradyne
$69.11

-1.13 (-1.61%)

01/13/20
EVER
01/13/20
UPGRADE
Target $85
EVER
Outperform
Teradyne upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst CJ Muse upgraded Teradyne to Outperform from In Line with a price target of $85, up from $65.
01/13/20
EVER
01/13/20
UPGRADE
Target $85
EVER
Outperform
Evercore upgrades Teradyne to Outperform on SOC market gains, IA bottoming
As previously reported, Evercore ISI analyst CJ Muse upgraded Teradyne to Outperform from In Line with a price target of $85, up from $65, as the SOC Test market is moving higher, Teradyne is gaining market share there, and the Industrial Automation business is now bottoming. Teradyne also has "excellent exposure" to 5G and within the factory automation megatrend, Muse tells investors.
10/25/19
DADA
10/25/19
NO CHANGE
Target $60
DADA
Neutral
Teradyne price target raised to $60 from $52 at DA Davidson
DA Davidson analyst Thomas Diffely raised his price target on Teradyne to $60 after its "impressive" beat-and-raise Q3 results, but notes that China and memory business - the weakest markets for many of the company's peers - drove the upside. The analyst states that Teradyne is outperforming due to "solid" NAND test demand and initial 5G infrastructure buildout in China, but keeps his Neutral rating given the company's "stretched valuation".
10/25/19
SBSH
10/25/19
NO CHANGE
Target $73
SBSH
Buy
Teradyne price target raised to $73 from $66 at Citi
Citi analyst Atif Malik raised his price target for Teradyne to $73 from $66 citing the company's "attractive 5G appeal." The analyst expects the company's multiple to expand given its exposure to 5G and keeps a Buy rating on the name.
FAF First American
$59.10

0.45 (0.77%)

06/19/19
SUSQ
06/19/19
INITIATION
SUSQ
Positive
Susquehanna starts First American with a Positive
As reported previously, Susquehanna analyst Jack Micenko initiated First American with a Positive rating. The analyst said his thesis is driven by both macro and company specific dynamics that are not priced in by the market. He believes consensus estimates are too conservative on mortgage volumes over the next 18 months and believes the fee-per-file growth continues to trend higher while capital return accelerates. Micenko has a $73 price target on First American shares.
06/19/19
SUSQ
06/19/19
INITIATION
SUSQ
Positive
First American initiated with a Positive at Susquehanna
04/29/19
04/29/19
DOWNGRADE

Neutral
First American downgraded to Neutral from Buy at Compass Point
As previously reported, Compass Point downgraded First American to Neutral from Buy. Analyst Chris Gamaitoni downgraded shares following the "solid" quarter citing valuation
12/08/19
KBWI
12/08/19
DOWNGRADE
Target $69
KBWI
Market Perform
First American downgraded to Market Perform from Outperform at Keefe Bruyette
Keefe Bruyette analyst Bose George downgraded First American Financial to Market Perform from Outperform with a $69 price target. The analyst cites valuation for the downgrade. With refinance volumes in the second of 2019 exceeding his earlier expectations, and assuming mortgage spreads hold fairly constant, George says his outlook for refinance volumes into 2020 now looks "less promising." Further, he notes that a number of stocks under his coverage with exposure to mortgage origination volumes have had a solid run this year.
META Metatec
$0.00

(0.00%)

KHRNF Khiron Life Sciences
$0.00

(0.00%)

TODAY'S FREE FLY STORIES

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

NSCO

Nesco Holdings

$5.12

0.025 (0.49%)

16:26
01/17/20
01/17
16:26
01/17/20
16:26
Syndicate
Nesco Holdings requests withdrawal of registration statement »

Nesco Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$18.54

-0.075 (-0.40%)

, CMCSA

Comcast

$47.48

0.62 (1.32%)

16:20
01/17/20
01/17
16:20
01/17/20
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

The major averages were…

GPS

Gap

$18.54

-0.075 (-0.40%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

CMCSK

Comcast

$0.00

(0.00%)

PLAY

Dave & Buster's

$47.35

5.3 (12.60%)

KKR

KKR

$31.20

0.7 (2.30%)

BA

Boeing

$324.11

-7.89 (-2.38%)

JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

SWK

Stanley Black & Decker

$172.63

2.18 (1.28%)

TWOU

2U

$22.84

1.05 (4.82%)

BE

Bloom Energy

$9.70

0.43 (4.64%)

MGPI

MGP Ingredients

$38.16

-14.74 (-27.86%)

FAST

Fastenal

$36.77

-0.55 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 20

    Jan

  • 22

    Jan

  • 23

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 26

    Feb

  • 27

    Feb

  • 09

    Mar

  • 17

    Mar

APLS

Apellis

$40.43

0.03 (0.07%)

16:18
01/17/20
01/17
16:18
01/17/20
16:18
Hot Stocks
Apellis CEO sells 30.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
01/17/20
01/17
16:17
01/17/20
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
01/17/20
01/17
16:16
01/17/20
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
01/17/20
01/17
16:15
01/17/20
16:15
General news
Treasury Market Summary »

Treasury Market Summary:…

LGC

Legacy Acquisition Corp

$10.33

(0.00%)

16:08
01/17/20
01/17
16:08
01/17/20
16:08
Hot Stocks
Legacy Acquisition Corp extends date to consummate proposed business combination »

Legacy Acquisition Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNUS

Genius Brands

$0.33

-0.015 (-4.41%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Syndicate
Breaking Syndicate news story on Genius Brands »

Genius Brands files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$90.21

1.28 (1.44%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Periodicals
Best Buy board opens investigation into CEO's personal conduct, WSJ says »

The board of Best Buy is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.